Posts – Page 88 – Safe Biologics

Patient Safety Depends on Prevention

June 29, 2011

By Andrew R. Spiegel
CEO, Colon Cancer Alliance
MedCity News

Prevention is a key message of the Colon Cancer Alliance. Over 80% of all cases of colorectal cancer can be prevented with recommended screenings. Despite its high incidence, colorectal cancer is one of the most detectable and, if found early enough, most treatable forms of cancer. With the widespread adoption of common screening practices, as many as 30,000 lives could be saved each year. Read More.

Patient Safety with Biosimilars: Not the Same, Only Similar

June 24, 2011

By Bruce S. Rubin, MD
Assistant Professor of Clinical Neurology, University of Miami Miller School of Medicine
Opposing Views

Scientific advancements in medicine are important achievements that improve quality of life for many people. One recent example is in the field of biotech medicines. But in the rush to make generic versions of these drugs, patient safety could be compromised. Read More

Washington State Medical Society – WSMA Reports – May/June 2011 – Biosimilars and the Cost-safety Balance

June 23, 2011

Less expensive, follow-on biologics are expected to be a boon to patients and Washington’s biotechnology industry. But as the FDA implements a new approval pathway for these complicated drugs, the medical community wants to ensure patient safety comes first.

European Medicines Agency and US Food and Drug Administration set up biosimilar ‘cluster’ and publish first report on interactions

June 23, 2011

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on biosimilar medicines. Clusters are topic areas of mutual interest for the two agencies, which they have identified as benefiting from the regular exchange of information and collaborative meetings. Biosimilar medicines is the latest addition to the existing list of topics, which already includes medicines to treat cancer, orphan medicines, medicines for children and blood-based products. Read more.

Safe Biologics

Patient Safety Depends on Prevention

Patient Safety with Biosimilars: Not the Same, Only Similar

Washington State Medical Society – WSMA Reports – May/June 2011 – Biosimilars and the Cost-safety Balance

European Medicines Agency and US Food and Drug Administration set up biosimilar ‘cluster’ and publish first report on interactions

Governor’s Life Sciences Summit & Annual Meeting

Stem Cell & Regenerative Medicine: Today and Tomorrow

WBBA/LSDF Open House

WBBA/LSDF Open House

Virginia Biotechnology Association

Virginia Biotechnology Association